Personalized mRNA Vaccine Shows Promise Against Pancreatic Cancer
A small study shows a personalized mRNA vaccine may significantly improve pancreatic cancer survival rates by generating long-lasting T cells that target cancer cells; half the participants who had a strong immune response remained cancer-free for over three years, far exceeding typical survival rat...
Personalized mRNA Vaccine Shows Promise Against Pancreatic Cancer
A small study shows a personalized mRNA vaccine may significantly improve pancreatic cancer survival rates by generating long-lasting T cells that target cancer cells; half the participants who had a strong immune response remained cancer-free for over three years, far exceeding typical survival rat...
Progress
40% Bias Score
mRNA Vaccine Shows Promise in Extending Survival for Early-Stage Pancreatic Cancer
A clinical trial at Memorial Sloan Kettering successfully used a customized mRNA vaccine alongside surgery and chemotherapy to treat early-stage pancreatic cancer, resulting in significantly extended survival time for eight of sixteen patients who showed strong immune responses and only two recurren...
mRNA Vaccine Shows Promise in Extending Survival for Early-Stage Pancreatic Cancer
A clinical trial at Memorial Sloan Kettering successfully used a customized mRNA vaccine alongside surgery and chemotherapy to treat early-stage pancreatic cancer, resulting in significantly extended survival time for eight of sixteen patients who showed strong immune responses and only two recurren...
Progress
40% Bias Score
World-First Personalized mRNA Cancer Vaccine Shows Promise in Treating Urinary Tract Cancer
A 75-year-old woman at Bari's Policlinico hospital became the first globally to receive a personalized mRNA cancer vaccine (cevumeran) alongside nivolumab immunotherapy after surgery for high-risk urinary tract cancer; this innovative treatment is designed to address specific tumor mutations, offeri...
World-First Personalized mRNA Cancer Vaccine Shows Promise in Treating Urinary Tract Cancer
A 75-year-old woman at Bari's Policlinico hospital became the first globally to receive a personalized mRNA cancer vaccine (cevumeran) alongside nivolumab immunotherapy after surgery for high-risk urinary tract cancer; this innovative treatment is designed to address specific tumor mutations, offeri...
Progress
56% Bias Score
Personalized mRNA Vaccines Show Promise in Pancreatic Cancer Treatment
A phase 1 clinical trial shows personalized mRNA vaccines generated a durable T-cell response in 50% of 16 patients with operable pancreatic cancer, lasting nearly eight years post-surgery, offering a potential new treatment for this deadly disease.
Personalized mRNA Vaccines Show Promise in Pancreatic Cancer Treatment
A phase 1 clinical trial shows personalized mRNA vaccines generated a durable T-cell response in 50% of 16 patients with operable pancreatic cancer, lasting nearly eight years post-surgery, offering a potential new treatment for this deadly disease.
Progress
44% Bias Score
Moderna Receives $590 Million for Accelerated Bird Flu Vaccine Development
The U.S. government awarded Moderna an additional $590 million to expedite development of an mRNA bird flu vaccine, bringing the total to $766 million, aiming to expand clinical trials for five subtypes and enhance pandemic preparedness amid 67 confirmed human cases since April 2024, with one death ...
Moderna Receives $590 Million for Accelerated Bird Flu Vaccine Development
The U.S. government awarded Moderna an additional $590 million to expedite development of an mRNA bird flu vaccine, bringing the total to $766 million, aiming to expand clinical trials for five subtypes and enhance pandemic preparedness amid 67 confirmed human cases since April 2024, with one death ...
Progress
36% Bias Score
Gamaleya Institute's mRNA Cancer Vaccine Shows Promise in Preclinical Trials
Preclinical trials of Gamaleya Research Institute's mRNA melanoma vaccine show tumor and metastasis regression in animals; human trials are planned for autumn 2025, initially combining the vaccine with other therapies for advanced cancers; future development aims for personalized, affordable vaccine...
Gamaleya Institute's mRNA Cancer Vaccine Shows Promise in Preclinical Trials
Preclinical trials of Gamaleya Research Institute's mRNA melanoma vaccine show tumor and metastasis regression in animals; human trials are planned for autumn 2025, initially combining the vaccine with other therapies for advanced cancers; future development aims for personalized, affordable vaccine...
Progress
56% Bias Score